ArticleJAMA neurology2019
Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Article in JAMA neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 2 syntheses or guidelines pooled it, 361 citations in OpenAlex.
- Expert Panel Consensus Guidelines of the German Society of Neuroradiology on the Use of Magnetic Resonance Imaging in the Diagnosis and Monitoring of Multiple Sclerosis.Clinical neuroradiology · 2026Guideline
- Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review.European journal of neurology · 2023Pooled it
- Clinical and radiological characteristics of MOG antibody-associated disease (MOGAD): a comparative study between pediatric and adult cohorts.Acta neurologica Belgica · 2026Article
- Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.Neurology · 2026Article
- Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease - MAGNIMS consensus recommendations.Nature reviews. Neurology · 2026Review
- Acute Steroid Associated Neurological Worsening in Spinal Dural Arteriovenous Fistula with Conus Medullaris Syndrome and "H-sign".Balkan medical journal · 2026Article
- Frequency and Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Accompanied by Fever: A Single-Center Retrospective Study.CNS neuroscience & therapeutics · 2026Article
- Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.JAMA neurology · 2026Article
- Intractable hiccups as a brainstem red flag: demyelinating disorders with emphasis on neuromyelitis optica spectrum disorder and area postrema syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Is MR Imaging of the Cervical Spinal Cord Sufficient for Patients with Suspected Multiple Sclerosis?Clinical neuroradiology · 2026Article
- Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis optica model induced by subarachnoid AQP4-IgG.The Journal of clinical investigation · 2026Article
- Early Response in Pediatric Transverse Myelitis: A Case-Control Study from Vietnam.Annals of Indian Academy of Neurology · 2026Article
- Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future.Frontiers in immunology · 2026Review
- Predictors of poor outcomes in neuroleptospirosis and differentiation from tuberculous meningitis: a cross-sectional analysis.Encephalitis (Seoul, Korea) · 2026Article
- Herpes simplex virus associated rhomboencephalitis mimicking demyelination: a case report.BMC infectious diseases · 2025Article
- Epidural labor analgesia in a pregnant woman with symptomatic recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease: a case report.JA clinical reports · 2025Article
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe Forms.International journal of molecular sciences · 2025Review
- Brain Characteristics in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder by 7.0 Tesla MRI.Annals of clinical and translational neurology · 2025Article
- Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Current neurology and neuroscience reports · 2025Review
- Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.Journal of neurology, neurosurgery, and psychiatry · 2025Article
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Funding
Abstract
Importance: Recognizing the characteristics of myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) myelitis is essential for early accurate diagnosis and treatment. Objective: To evaluate the clinical, radiologic, and prognostic features of MOG-IgG myelitis and compare with myelitis with aquaporin-4-IgG (AQP4-IgG) and multiple sclerosis (MS). Design, Setting, and Participants: We retrospectively identified 199 MOG-IgG-positive Mayo Clinic patients from January 1, 2000, through December 31, 2017, through our neuroimmunology laboratory. Fifty-four patients met inclusion criteria of (1) clinical myelitis; (2) MOG-IgG positivity; and (3) medical records available. We excluded 145 patients without documented myelitis. Myelitis of AQP4-IgG (n = 46) and MS (n = 26) were used for comparison. Main Outcomes and Measures: Outcome variables included modified Rankin score and need for gait aid. A neuroradiologist analyzed spine magnetic resonance imaging of patients with MOG-IgG and control patients blinded to diagnosis. Results: Of 54 included patients with MOG-IgG myelitis, the median age was 25 years (range, 3-73 years) and 24 were women (44%). Isolated transverse myelitis was the initial manifestation in 29 patients (54%), and 10 (19%) were initially diagnosed as having viral/postviral acute flaccid myelitis. Cerebrospinal fluid-elevated oligoclonal bands occurred in 1 of 38 (3%). At final follow-up (median, 24 months; range, 2-120 months), 32 patients (59%) had developed 1 or more relapses of optic neuritis (n = 31); transverse myelitis (n = 7); or acute disseminated encephalomyelitis (n = 1). Clinical features favoring MOG-IgG myelitis vs AQP4-IgG or MS myelitis included prodromal symptoms and concurrent acute disseminated encephalomyelitis. Magnetic resonance imaging features favoring MOG-IgG over AQP4-IgG or MS myelitis were T2-signal abnormality confined to gray matter (sagittal line and axial H sign) and lack of enhancement. Longitudinally extensive T2 lesions were of similar frequency in MOG-IgG and AQP4-IgG myelitis (37 of 47 [79%] vs 28 of 34 [82%]; P = .52) but not found in MS. Multiple spinal cord lesions and conus involvement were more frequent with MOG-IgG than AQP4-IgG but not different from MS. Wheelchair dependence at myelitis nadir occurred in one-third of patients with MOG-IgG and AQP4-IgG but never with MS, although patients with MOG-IgG myelitis recovered better than those with AQP4-IgG. Conclusions and Relevance: Myelitis is an early manifestation of MOG-IgG-related disease and may have a clinical phenotype of acute flaccid myelitis. We identified a variety of clinical and magnetic resonance imaging features that may help clinicians identify those at risk in whom MOG-IgG should be tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.